ScreenerHero

COGTCogent Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · cogentbio.com
36.73USD-0.33%Mkt Cap: 6.37B $P/E: —

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyros…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.37B $
Enterprise Value5.65B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-328.94M $
Revenue/Share—
Last Price36.73 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees258
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-31.92
PEG—
EV/EBITDA-14.61
EV/Revenue—
P/S—
P/B12.96
EPS (TTM)-2.07
EPS (Forward)-1.11
52W Range
11.5378% of range43.73
52W High43.73 USD
52W Low11.53 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-51.69%
ROA-35.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-264.44M $
CapEx (TTM)1.55M $
FCF Margin—
FCF Yield-2.92%
Net Debt-548.04M $
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.38
Current Ratio13.57
Quick Ratio13.36
Book Value/Sh2.724 USD
Cash/Share4.565 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 9, 2020
Splits
Last Split1:4
Split DateNov 9, 2020
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)55.82 USD
Upside (mean)+52.0%
Target Range45.00 USD – 62.00 USD
$45.00+52.0% to mean$62.00
# Analysts11
Ownership
Shares Out.173.52M
Float172.56M
Insiders0.42%
Institutions115.08%
Short Interest
Short Ratio8.0d
Short % Float10.49%
Short % Out.10.43%
Shares Short17.89M
Short (prev mo.)16.35M
Technical
SMA 5038.23 (-3.9%)
SMA 20036.37 (+1.0%)
Beta0.33
S&P 52W Chg18.16%
Avg Vol (30d)1.90M
Avg Vol (10d)1.78M
Technical Indicators
RSI (14)41.0
MACD-0.3035
MACD Signal0.3098
MACD Hist.-0.6133
BB Upper43.53 USD
BB Middle39.75 USD
BB Lower35.97 USD
BB Width19.02%
ATR (14)1.848 USD
Vol Ratio (20d)1.29x